Hendley & Co. Inc. Cuts Position in AstraZeneca PLC $AZNCF

Hendley & Co. Inc. trimmed its holdings in shares of AstraZeneca PLC (OTCMKTS:AZNCF) by 50.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,377 shares of the company’s stock after selling 32,428 shares during the period. AstraZeneca comprises 2.4% of Hendley & Co. Inc.’s investment portfolio, making the stock its 19th largest position. Hendley & Co. Inc.’s holdings in AstraZeneca were worth $6,385,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of AZNCF. Athena Wealth Management LLC acquired a new stake in shares of AstraZeneca in the first quarter worth $1,911,000. AdvisorNet Financial Inc acquired a new position in shares of AstraZeneca during the 1st quarter valued at $2,361,000. Defined Wealth Management LLC purchased a new stake in AstraZeneca during the 1st quarter worth $255,000. SVB Wealth LLC purchased a new stake in AstraZeneca during the 1st quarter worth $556,000. Finally, Bell Investment Advisors Inc purchased a new stake in AstraZeneca during the 1st quarter worth $39,000. 40.87% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

Shares of OTCMKTS AZNCF opened at $187.10 on Tuesday. The stock has a fifty day moving average price of $187.10 and a 200 day moving average price of $186.10. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.